Parathyroid growth and suppression in renal failure

Seminars in Dialysis

Volumn 19, Issue 3, 2006, Pages 238-245

  Lewin, Ewa ^a,b   Huan, Jinxing ^a   Olgaard, Klaus ^a  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE; PTH PROTEIN, HUMAN;

ANIMAL; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; GROWTH, DEVELOPMENT AND AGING; HUMAN; HYPERPLASIA; METABOLISM; PARATHYROID GLAND; PATHOLOGY; REVIEW; SECONDARY HYPERPARATHYROIDISM; UREMIA;

ANIMALS; CELL PROLIFERATION; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPLASIA; KIDNEY FAILURE, CHRONIC; PARATHYROID GLANDS; PARATHYROID HORMONE; UREMIA;

EID: 33646673109     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00161.x     Document Type: Review

References (117)

1. Murayama A, Takeyama K, Kitanaka S, Kodera Y, Kawaguchi Y, Hosoya T, Kato S: Positive and negative regulations of the renal 25-hydroxyvitamin D3, 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals. Endocrinology 140: 2224 2231, 1999
2. Shinki T, Shimada H, Wakino S, Anazawa H, Hayashi M, Saruta T, DeLuca HF, Suda T: Cloning and expression of rat 25-hydroxyvitamin D3-1alpha-hydroxylase cDNA. Proc Natl Acad Sci USA 94: 12920 12925, 1997
3. Brenza HL, Kimmel-Jehan C, Jehan F, Shinki T, Wakino S, Anazawa H, Suda T, DeLuca HF: Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc Natl Acad Sci USA 95: 1387 1391, 1998
4. Murayama A, Takeyama K, Kitanaka S, Kodera Y, Hosoya T, Kato S: The promoter of the human 25-hydroxyvitamin D3 1 alpha-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1 alpha, 25(OH)2D3. Biochem Biophys Res Commun 249: 11 16, 1998
5. Fraser DR, Kodicek E: Regulation of 25-hydroxycholecalciferol-1- hydroxylase activity in kidney by parathyroid hormone. Nat New Biol 241: 163 166, 1973
6. Kilav R, Silver J, Biber J, Murer H, Naveh-Many T: Coordinate regulation of rat renal parathyroid hormone receptor mRNA and Na-Pi cotransporter mRNA and protein. Am J Physiol 268: F1017 F1022, 1995
7. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, Hernandez A, de Bonis E, Darias E, Gonzalez-Posada JM, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 47: 1434 1442, 1995
8. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 43: 436 442, 1993
9. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y: Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 26: 836 844, 1995
10. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 26: 622 631, 1995
11. Monier-Faugere MC, Malluche HH: Trends in renal osteodystrophy. a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 11 suppl 3 111 120, 1996
12. Hruska K: New concepts in renal osteodystrophy. Nephrol Dial Transplant 13: 2755 2760, 1998
13. Malluche HH, Monier-Faugere MC: Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 38: S62 S67, 1992
14. Mucsi I, Hercz G: Adynamic bone disease: pathogenesis, diagnosis and clinical relevance. Curr Opin Nephrol Hypertens 6: 356 361, 1997
15. Massry SG, Coburn JW, Lee DB, Jowsey J, Kleeman CR: Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann Intern Med 78: 357 364, 1973
16. Olgaard K, Arbelaez M, Schwartz J, Klahr S, Slatopolsky E: Abnormal skeletal response to parathyroid hormone in dogs with chronic uremia. Calcif Tissue Int 34: 403 407, 1982
17. Lewin E, Olgaard K: Calciotropic hormones and the skeleton in uraemia. Eur J Clin Invest 29: 466 468, 1999
18. Massry SG: Parathyroid hormone: a uremic toxin. Adv Exp Med Biol 223: 1 17, 1987
19. Bro S, Olgaard K: Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 30: 606 620, 1997
20. Naveh-Many T, Rahamimov R, Livni N, Silver J: Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 96: 1786 1793, 1995
21. Silver J, Kilav R, Naveh-Many T: Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 283: F367 F376, 2002
22. Brown AJ, Dusso A, Lopez-Hilker S, Lewis-Finch J, Grooms P, Slatopolsky E: 1,25-(OH)2D receptors are decreased in parathyroid glands from chronically uremic dogs. Kidney Int 35: 19 23, 1989
23. Denda M, Finch J, Slatopolsky E: Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 28: 596 602, 1996
24. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ: Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97: 2534 2540, 1996
25. Drueke TB: Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 11: 1141 1152, 2000
26. Naveh-Many T, Silver J: Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 86: 1313 1319, 1990
27. Moallem E, Kilav R, Silver J, Naveh-Many T: RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 273: 5253 5259, 1998
28. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366: 575 580, 1993
29. Lewin E, Garfia B, Recio FL, Rodriguez M, Olgaard K: Persistent downregulation of calcium-sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation. J Am Soc Nephrol 13: 2110 2116, 2002
30. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51: 328 336, 1997
31. Brown AJ, Ritter CS, Finch JL, Slatopolsky EA: Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int 55: 1284 1292, 1999
32. Kifor O, Moore FD Jr., Wang P, Goldstein M, Vassilev P, Kifor I, Hebert SC, Brown EM: Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81: 1598 1606, 1996
33. Nielsen PK, Feldt-Rasmussen U, Olgaard K: A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells. Nephrol Dial Transplant 11: 1762 1768, 1996
34. Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, Rodriguez M: Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 11: 970 976, 1996
35. Almaden Y, Hernandez A, Torregrosa V, Canalejo A, Sabate L, Fernandez CL, Campistol JM, Torres A, Rodriguez M: High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 9: 1845 1852, 1998
36. Martin DR, Ritter CS, Slatopolsky E, Brown AJ: Acute regulation of parathyroid hormone by dietary phosphate. Am J Physiol Endocrinol Metab 289: E729 E734, 2005
37. Naveh-Many T, Marx R, Keshet E, Pike JW, Silver J: Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest 86: 1968 1975, 1990
38. Silver J, Yalcindag C, Sela-Brown A, Kilav R, Naveh-Many T: Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate. Kidney Int Suppl 73: S2 S7, 1999
39. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78: 1296 1301, 1986
40. Demay MB, Kiernan MS, DeLuca HF, Kronenberg HM: Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 89: 8097 8101, 1992
41. Liu SM, Koszewski N, Lupez M, Malluche HH, Olivera A, Russell J: Characterization of a response element in the 5′-flanking region of the avian (chicken) PTH gene that mediates negative regulation of gene transcription by 1,25-dihydroxyvitamin D3 and binds the vitamin D3 receptor. Mol Endocrinol 10: 206 215, 1996
42. Merke J, Hugel U, Zlotkowski A, Szabo A, Bommer J, Mall G, Ritz E: Diminished parathyroid 1,25(OH)2D3 receptors in experimental uremia. Kidney Int 32: 350 353, 1987
43. Korkor AB: Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316: 1573 1577, 1987
44. Yalcindag C, Silver J, Naveh-Many T: Mechanism of increased parathyroid hormone mRNA in experimental uremia: roles of protein RNA binding and RNA degradation. J Am Soc Nephrol 10: 2562 2568, 1999
45. Kilav R, Silver J, Naveh-Many T: A conserved cis-acting element in the parathyroid hormone 3′-untranslated region is sufficient for regulation of RNA stability by calcium and phosphate. J Biol Chem 276: 8727 8733, 2001
46. Lewin E, Almaden Y, Rodriguez M, Olgaard K: PTHrP enhances the secretory response of PTH to a hypocalcemic stimulus in rat parathyroid glands. Kidney Int 58: 71 81, 2000
47. Lewin E, Garfia B, Almaden Y, Rodriguez M, Olgaard K: Autoregulation in the parathyroid glands by PTH/PTHrP receptor ligands in normal and uremic rats. Kidney Int 64: 63 70, 2003
48. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A: A novel mechanism for skeletal resistance in uremia. Kidney Int 58: 753 761, 2000
49. Silver J, Kilav R, Sela-Brown A, Naveh-Many T: Molecular mechanisms of secondary hyperparathyroidism. Pediatr Nephrol 14: 626 628, 2000
50. Soliman E, Canaff L, Fox J, Hendy GN: In vivo regulation of chromogranin A messenger ribonucleic acid in the parathyroid by 1,25-dihydroxyvitamin D: studies in normal rats and in chronic renal insufficiency. Endocrinology 138: 2596 2600, 1997
51. Parfitt AM: The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 52: 3 9, 1997
52. Wang Q, Palnitkar S, Parfitt AM: Parathyroid cell proliferation in the rat: effect of age and of phosphate administration and recovery. Endocrinology 137: 4558 4562, 1996
53. Tominaga Y, Takagi H: Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens 5: 336 341, 1996
54. Rodriguez M, Canalejo A, Garfia B, Aguilera E, Almaden Y: Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int 61 suppl 80 155 160, 2002
55. Valimaki S, Farnebo F, Forsberg L, Larsson C, Farnebo LO: Heterogeneous expression of receptor mRNAs in parathyroid glands of secondary hyperparathyroidism. Kidney Int 60: 1666 1675, 2001
56. Matsushita H, Hara M, Endo Y, Shishiba Y, Hara S, Ubara Y, Nakazawa H, Suzuki N, Kawaminami K, Kido T, Li Q, Grimelius L: Proliferation of parathyroid cells negatively correlates with expression of parathyroid hormone-related protein in secondary parathyroid hyperplasia. Kidney Int 55: 130 138, 1999
57. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke TB: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 95: 2047 2053, 1995
58. Falchetti A, Bale AE, Amorosi A, Bordi C, Cicchi P, Bandini S, Marx SJ, Brandi ML: Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J Clin Endocrinol Metab 76: 139 144, 1993
59. Miki H, Sumitomo M, Inoue H, Kita S, Monden Y: Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Surgery 120: 897 901, 1996
60. Carling T, Rastad J, Szabo E, Westin G, Akerstrom G: Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab 85: 2000 2003, 2000
61. Szabo A, Merke J, Beier E, Mall G, Ritz E: 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 35: 1049 1056, 1989
62. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J: Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57: 50 58, 2000
63. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D: Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67: 467 476, 2005
64. Dusso AS, Pavlopoulos T, Naumovich L, Lu Y, Finch J, Brown AJ, Morrissey J, Slatopolsky E: p21 (WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int 59: 855 865, 2001
65. Yi H, Fukagawa M, Yamato H, Kumagai M, Watanabe T, Kurokawa K: Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Nephron 70: 242 248, 1995
66. Slatopolsky E, Caglar S, Gradowska L, Canterbury J, Reiss E, Bricker NS: On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int 2: 147 151, 1972
67. Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso AS: p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 60: 2109 2117, 2001
68. Cozzolino M, Brancaccio D, Gallieni M, Galassi A, Slatopolsky E, Dusso A: Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol 18: 5 8, 2005
69. Cozzolino M, Lu Y, Sato T, Yang J, Suarez IG, Brancaccio D, Slatopolsky E, Dusso AS: A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol 289: F1096 F1102, 2005
70. Gogusev J, Duchambon P, Stoermann-Chopard C, Giovannini M, Sarfati E, Drueke TB: De novo expression of transforming growth factor-alpha in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism. Nephrol Dial Transplant 11: 2155 2162, 1996
71. Almaden Y, Felsenfeld AJ, Rodriguez M, Canadillas S, Luque F, Bas A, Bravo J, Torregrosa V, Palma A, Ramos B, Sanchez C, Martin-Malo A, Canalejo A: Proliferation in hyperplastic human and normal rat parathyroid glands: role of phosphate, calcitriol, and gender. Kidney Int 64: 2311 2317, 2003
72. Zhang P, Duchambon P, Gogusev J, Nabarra B, Sarfati E, Bourdeau A, Drueke TB: Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism. Kidney Int 57: 437 445, 2000
73. Wada M, Furuya Y, Sakiyama JI, Kobayashi N, Miyata S, Ishii H, Nagano N: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100: 2977 2983, 1997
74. Henry HL, Taylor AN, Norman AW: Response of chick parathyroid glands to the vitamin D metabolites, 1,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol. J Nutr 107: 1918 1926, 1977
75. Fukagawa M, Okazaki R, Takano K, Kaname S, Ogata E, Kitaoka M, Harada S, Sekine N, Matsumoto T, Kurokawa K: Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 323: 421 422, 1990
76. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K: Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 68: 221 228, 1994
77. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45: 1710 1721, 1994
78. Jara A, Gonzalez S, Felsenfeld AJ, Chacon C, Valdivieso A, Jalil R, Chuaqui B: Failure of high doses of calcitriol and hypercalcaemia to induce apoptosis in hyperplastic parathyroid glands of azotaemic rats. Nephrol Dial Transplant 16: 506 512, 2001
79. Canalejo A, Almaden Y, Torregrosa V, Gomez-Villamandos JC, Ramos B, Campistol JM, Felsenfeld AJ, Rodriguez M: The in vitro effect of calcitriol on parathyroid cell proliferation and apoptosis. J Am Soc Nephrol 11: 1865 1872, 2000
80. Lewin E, Wang W, Olgaard K: Reversibility of experimental secondary hyperparathyroidism. Kidney Int 52: 1232 1241, 1997
81. Lewin E: Parathyroid hormone regulation in normal and uremic rats. Reversibility of secondary hyperparathyroidism after experimental kidney transplantation. Dan Med Bull 51: 184 206, 2004
82. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1 S201, 2003
83. Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51: 18 26, 1999
84. Slatopolsky EA, Burke SK, Dillon MA: RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The Renagel Study Group. Kidney Int 55: 299 307, 1999
85. Brandi L, Daugaard H, Tvedegaard E, Storm T, Olgaard K: Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron 53: 194 200, 1989
86. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9: 1427 1432, 1998
87. Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Kurokawa K: Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 38: S147 S151, 2001
88. Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y: Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 32: 238 246, 1998
89. Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358 363, 1995
90. Rapoport J, Mostoslavski M, Ben David A, Knecht A, Blau A, Arad J, Zlotnik M, Chaimovitz C: Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy. Nephron 72: 150 154, 1996
91. Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW: Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 43: 877 890, 2004
92. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ: The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int 63: 248 254, 2003
93. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516 1525, 2004
94. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 42: 1191 1198, 1992
95. Schindler S, Mannstadt M, Urena P, Segre GV, Stein G: PTH secretion in patients with chronic renal failure assessed by a modified CiCa clamp method: effects of 1-year calcitriol therapy. Clin Nephrol 61: 253 260, 2004
96. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D'Amour P: Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 81: 3923 3929, 1996
97. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, Gao P, Cantor T, D'Amour P: Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Eur J Endocrinol 147: 123 131, 2002
98. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D'Amour P: A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44: 805 809, 1998
99. Dumoulin G, Hory B, Nguyen NU, Bresson C, Fournier V, Bouhaddi M, Chalopin JM, Saint-Hillier Y, Regnard J: No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am J Kidney Dis 29: 746 753, 1997
100. Reinhardt W, Bartelworth H, Jockenhovel F, Schmidt-Gayk H, Witzke O, Wagner K, Heemann U, Reinwein D, Philipp T, Mann K: Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 13: 434 440, 1998
101. Botha JF, Botha JR: Parathyroid function after successful renal transplantation. S Afr J Surg 35: 113 116, 1997
102. Claesson K, Hellman P, Frodin L, Rastad J: Prospective study of calcium homeostasis after renal transplantation. World J Surg 22: 635 641, 1998
103. Uchida K, Tominaga Y, Tanaka Y, Takagi H: Renal transplantation and secondary hyperparathyroidism. Semin Surg Oncol 13: 97 103, 1997
104. D'Alessandro AM, Melzer JS, Pirsch JD, Sollinger HW, Kalayoglu M, Vernon WB, Belzer FO, Starling JR: Tertiary hyperparathyroidism after renal transplantation: operative indications. Surgery 106: 1049 1055, 1989
105. Parfitt AM: Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 8: 92 112, 1982
106. Schmid T, Muller P, Spelsberg F: Parathyroidectomy after renal transplantation. a retrospective analysis of long-term outcome. Nephrol Dial Transplant 12: 2393 2396, 1997
107. Messa P, Sindici C, Cannella G, Miotti V, Risaliti A, Gropuzzo M, Di Loreto PL, Bresadola F, Mioni G: Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 54: 1704 1713, 1998
108. Kinnaert P, Nagy N, Decoster-Gervy C, De Pauw L, Salmon I, Vereerstraeten P: Persistent hyperparathyroidism requiring surgical treatment after kidney transplantation. World J Surg 24: 1391 1395, 2000
109. Torres A, Lorenzo V, Salido E: Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 13: 551 558, 2002
110. McCarron DA, Muther RS, Lenfesty B, Bennett WM: Parathyroid function in persistent hyperparathyroidism: relationship to gland size. Kidney Int 22: 662 670, 1982
111. Lewin E: Involution of the parathyroid glands after renal transplantation. Curr Opin Nephrol Hypertens 12: 363 371, 2003
112. Tominaga Y, Sato K, Tanaka Y, Numano M, Uchida K, Takagi H: Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure. Clin Nephrol 44 suppl 1 S42 S47, 1995
113. Bell CD, Vidal S, Kovacs K, Anderson J, Rotondo F: Cox-2 expression in the oxyphilic cells of the normal, hyperplastic, and adenomatous parathyroid gland. Endocr Pathol 15: 29 38, 2004
114. Finch JL, Dusso AS, Pavlopoulos T, Slatopolsky EA: Relative potencies of 1,25-(OH)(2)D(3) and 19-Nor-1,25-(OH)(2)D(2) on inducing differentiation and markers of bone formation in MG-63 cells. J Am Soc Nephrol 12: 1468 1474, 2001
115. Bedetti CD, Dekker A, Watson CG: Functioning oxyphil cell adenoma of the parathyroid gland (a clinicopathologic study of ten patients with hyperparathyroidism. Hum Pathol 15: 1121 1126, 1984
116. Ordonez NG, Ibanez ML, Mackay B, Samaan NA, Hickey RC: Functioning oxyphil cell adenomas of parathyroid gland: immunoperoxidase evidence of hormonal activity in oxyphil cells. Am J Clin Pathol 78: 681 689, 1982
117. Matsushita H, Usui M, Hara M, Shishiba Y, Nakazawa H, Honda K, Torigoe K, Kohno K, Kurimoto M: Co-secretion of parathyroid hormone and parathyroid-hormone-related protein via a regulated pathway in human parathyroid adenoma cells. Am J Pathol 150: 861 871, 1997